Pardoprunox
id:
pardoprunox-290-6839623
title:
Pardoprunox
text:
Pardoprunox (INN) is an antiparkinsonian drug developed by Solvay for the treatment of Parkinson's disease that reached phase III clinical trials before being discontinued. It was also being investigated for the treatment of depression and anxiety but these indications appear to have been abandoned as well. Pardoprunox acts as a D2 and D3 receptor partial agonist and 5-HT1A receptor full agonist. It also binds to D4, α1-adrenergic, α2-adrenergic, and 5-HT7 receptors with lower affinity. Relative
brand slug:
wiki
category slug:
encyclopedia
description:
Antiparkinsonian compound researched for the treatment of depression and anxiety disorders
original url:
https://en.wikipedia.org/wiki/Pardoprunox
date created:
date modified:
2022-04-29T15:52:12Z
main entity:
{"identifier":"Q7136602","url":"https://www.wikidata.org/entity/Q7136602"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/6/69/Pardoprunox.png","width":1161,"height":1665}
fields total:
13
integrity:
15